Last reviewed · How we verify
RUBELLA VIRUS VACCINE LIVE
Rubella Virus Vaccine Live is a marketed vaccine with a key composition patent expiring in 2028. The vaccine holds a strong market position due to its established efficacy and safety profile. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | RUBELLA VIRUS VACCINE LIVE |
|---|---|
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RUBELLA VIRUS VACCINE LIVE CI brief — competitive landscape report
- RUBELLA VIRUS VACCINE LIVE updates RSS · CI watch RSS